Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164097 · ClinicalTrials.gov registry record · Phase 1
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
A Phase 1 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02164097 is a Phase 1 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 4 participants.
The verdict
NCT02164097, a Phase 1 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will be with pediatric patients who have refractory/recurrent solid tumors. They will receive standard chemotherapy (ICE) and we are investigating if the addition of a new drug, ODSH, will help to increase the time of their platelet recovery after ICE chemotherapy.The purpose of this study is to evaluate the safety and tolerability of ODSH in pediatric patients receiving "ICE" chemotherapy.
Interventions
- DRUG ODSH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164097
The ClinicalTrials.gov registry entry for NCT02164097 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ODSH is the first listed.
NCT02164097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164097 about?
NCT02164097 is a clinical study titled "ODSH + ICE Chemotherapy in Pediatric Solid Tumors". This study will be with pediatric patients who have refractory/recurrent solid tumors. They will receive standard chemotherapy (ICE) and we are investigating if the addition of a new drug, ODSH, will help to increase the time of their platelet recovery after ICE chemotherapy.The purpose of this stud...
What is the current status of trial NCT02164097?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02164097?
The interventions under investigation include: ODSH (DRUG).
Who is sponsoring clinical trial NCT02164097?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.